Erasca reports 57% preliminary response rate for ERAS-0015 in 2L+ KRAS G12X pancreatic cancer trial
ERAS•Development plans
Development plans include a potentially registration-enabling NSCLC trial in 1H 2027 and a Phase 3 PDAC first-line trial in 2027.
Updated Phase 1 data for ERAS-0015
Erasca reported updated preliminary Phase 1 AURORAS-1 data for pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors.
- In second-line or later KRAS G12X pancreatic cancer, uORR at 8 weeks was 57% (N=7) at the 32 mg once-daily expansion dose.
- Safety profile remained broadly consistent with prior disclosure; no dose-limiting toxicities were reported, and no treatment discontinuations due to TRAEs.
- One pneumonitis case progressed to a fatal outcome following withdrawal of supportive care.
Related News
Albertsons accused of overworking pharmacists, fueling opioid crisis as Washington state trial begins
ACI•
Concrete Pumping Holdings director, 10% owner Brent Stevens disposes of shares worth $1.08 million
BBCP•
